Latest News

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.
Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

July 2nd 2025

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Exercise-Based Regimen Shows Efficacy Promise in CRC
Exercise-Based Regimen Shows Efficacy Promise in CRC

June 30th 2025

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.
Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

June 28th 2025

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.
Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

June 27th 2025

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.
Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

June 27th 2025

Video Series
Video Interviews
Podcasts
Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRC
Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, Talks COLOMATE Platform in CRC With Experts
Oncology Peer Review On-The-Go

More News